Production (Stage)
Galmed Pharmaceuticals Ltd.
GLMD
$1.61
-$0.07-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -18.97% | -18.97% | -11.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -46.66% | -46.66% | -49.19% |
| Operating Income | -- | -- | 46.66% | 46.66% | 49.19% |
| Income Before Tax | -- | -- | 48.45% | 48.45% | 53.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 48.45% | 48.45% | 53.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 48.45% | 48.45% | 53.10% |
| EBIT | -- | -- | 46.66% | 46.66% | 49.19% |
| EBITDA | -- | -- | 47.33% | 47.33% | 49.29% |
| EPS Basic | -- | -- | 66.42% | 67.29% | 62.95% |
| Normalized Basic EPS | -- | -- | 68.22% | 69.12% | 64.35% |
| EPS Diluted | -- | -- | 66.42% | 67.29% | 62.95% |
| Normalized Diluted EPS | -- | -- | 68.22% | 69.12% | 64.35% |
| Average Basic Shares Outstanding | -- | -- | 143.70% | 171.03% | 102.68% |
| Average Diluted Shares Outstanding | -- | -- | 143.70% | 171.03% | 102.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |